MAKO Surgical Corp. Announces Addition of Senior Executive to Management Team

MAKO Surgical Corp. Announces Addition of Senior Executive to Management Team

FORT LAUDERDALE, Fla., June 3, 2013 (GLOBE NEWSWIRE) -- MAKO Surgical Corp.
(Nasdaq:MAKO), a medical device company that markets its RIO® Robotic Arm
Interactive Orthopedic surgical platform, MAKOplasty® joint specific
applications and proprietary RESTORIS® implants that together enable
orthopedic surgeons to consistently, reproducibly and precisely treat patient
specific osteoarthritic disease, today announced that Ian Dawson has been
appointed to the position of Senior Vice President of Marketing, assuming
responsibility for MAKO's commercial marketing activities, which were formerly
overseen by Ivan Delevic, who is transitioning to the position of Senior Vice
President of Corporate Development.  Mr. Dawson and Mr. Delevic will report
to Maurice R. Ferré, M.D., MAKO's President and Chief Executive Officer.

Mr. Dawson has over 25 years of experience in marketing, with the majority of
such experience in the medical device field. From June 2008 through May 2013,
Mr. Dawson served as Vice President of North America Marketing for Smith &
Nephew Advanced Wound Management, a manufacturer and supplier of advanced
wound dressings and devices, where he was responsible for managing the entire
marketing function for North America. From May 2004 to June 2008, Mr. Dawson
held various marketing leadership positions with Zimmer, Inc., a manufacturer
and supplier of orthopedic implants and surgical products, including Senior
Director of U.S. Knee Marketing, where he was responsible for directing all
marketing programs and activities related to Zimmer's knee products. From
July 2001 to April 2004, he served as the Vice President - Product Group Knee,
for Centerpulse Orthopedics Ltd., a manufacturer and supplier of orthopedic
implants. Mr. Dawson holds a B.S. in Applied Biology from Chelsea College,
University of London and a Diploma in Management Studies from Exeter College
of Plymouth Polytechnic.

"Based on his impressive background and experience in orthopedics, Ian will be
a valuable addition to the MAKO team," said Dr. Ferré.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its RIO®
Robotic-Arm Interactive Orthopedic system, joint specific applications for the
knee and hip, and proprietary RESTORIS® implants for orthopedic procedures
called MAKOplasty®. The RIO is a surgeon-interactive tactile surgical platform
that incorporates a robotic arm and patient-specific visualization technology,
which enables precise, consistently reproducible bone resection for the
accurate insertion and alignment of MAKO's RESTORIS implants. The MAKOplasty
solution incorporates technologies enabled by an intellectual property
portfolio including more than 300 U.S. and foreign, owned and licensed,
patents and patent applications. Additional information can be found at
www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other
things, statements related to expectations, goals, plans, objectives and
future events. MAKO intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained in Section
21E of the Securities Exchange Act of 1934 and the Private Securities Reform
Act of 1995. In some cases, forward-looking statements can be identified by
the following words: "may," "will," "could," "would," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "continue," "ongoing," or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain
these words. These statements are based on the current estimates and
assumptions of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances, assumptions and
other factors that may cause actual results to differ materially from those
indicated by forward-looking statements, many of which are beyond MAKO's
ability to control or predict. Such factors, among others, may have a material
adverse effect on MAKO's business, financial condition and results of
operations and may include the potentially significant impact of a continued
economic downturn or delayed economic recovery on the ability of MAKO's
customers to secure adequate funding, including access to credit, for the
purchase of MAKO's products or cause MAKO's customers to delay a purchasing
decision, changes in general economic conditions and credit conditions,
changes in the availability of capital and financing sources for our company
and our customers, unanticipated changes in the timing and duration of the
sales cycle for MAKO's products or the vetting process undertaken by
prospective customers, changes in competitive conditions and prices in MAKO's
markets, changes in the relationship between supply of and demand for our
products, fluctuations in costs and availability of raw materials, finished
goods, and labor, changes in other significant operating expenses, slowdowns,
delays, or inefficiencies in MAKO's product research and development cycles,
unanticipated issues relating to intended product launches, decreases in sales
of MAKO's principal product lines, decreases in utilization of MAKO's
principal product lines or in procedure volume or system utilizations,
increases in expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or foreign
regulatory requirements related to MAKO's current products, including
initiating and communicating product actions or product recalls and meeting
Medical Device Reporting requirements and other required reporting to the
United States Food and Drug Administration, or securing regulatory clearance
or approvals for new products or upgrades or changes to MAKO's current
products, developments adversely affecting our actual and potential sales
activities outside the United States, increases in cost containment efforts by
group purchasing organizations, the impact of the United States healthcare
reform legislation enacted in March 2010 on hospital spending, reimbursement,
unanticipated changes in reimbursement to our customers for our products, and
the taxing of medical device companies, any unanticipated impact arising out
of the securities class action or any other litigation, inquiry, or
investigation brought against MAKO, loss of key management and other personnel
or inability to attract such management and other personnel, increases in
costs of retaining a direct sales force and building a distributor network,
unanticipated issues related to, or unanticipated changes in or difficulties
associated with, the recruitment of agents and distributors of our products,
and unanticipated intellectual property expenditures required to develop,
market, and defend MAKO's products or market position. These and other risks
are described in greater detail under Item 1A, "Risk Factors," in MAKO's
periodic filings with the Securities and Exchange Commission, including MAKO's
annual report on Form 10-K for the year ended December 31, 2012 filed on
February 28, 2013. Given these uncertainties, undue reliance should not be
placed on these forward-looking statements. MAKO does not undertake any
obligation to release any revisions to these forward-looking statements
publicly to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events.

"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo, whether
standing alone or in connection with the words "MAKO Surgical Corp." are
trademarks of MAKO Surgical Corp.

CONTACT: Investors:
         MAKO Surgical Corp.
         954-628-1706
         investorrelations@makosurgical.com
        
         or
        
         Westwicke Partners
         Mark Klausner
         443-213-0500
         makosurgical@westwicke.com
 
Press spacebar to pause and continue. Press esc to stop.